Keywords
How to Cite
Abstract
Activation of AKT signaling pathway and mTOR substrates of kidney tumor tissue occurs by improving AKT, its phosphorylated form, the serine / threonine proteinkinase m-TOR, the exchange regulator glycogen GSK-3-beta and also the inhibitor of 4E-BP1transcription. Increasing the size of primary tumor is followed by increasing the content of therein c-Raf and decreasing the content of phospho-m-TOR. The development of disseminated forms of the disease was associated with a reduction PTEN and phospho-AKT in tumor.References
Спирина Л.В., Усынин Е.А., Кондакова И.В. и др. Экспрессия транскрипционных факторов, сосудистого эндотелиального фактора роста и активность внутриклеточных протеиназ у больных с локализованным и диссеминированным раком почки // Сиб. онкол. журнал. - 2014. - № 4. - С. 31-38.
Спирина Л.В., Кондакова И.В., Усынин Е.А. и др. Активность протеасом и содержание ростовых факторов при раке почки, мочевого пузыря и эндометрия // Росс. онкол. журнал. - 2010. - № 1. - С. 23 - 25.
Юнусова Н. В., Спирина Л. В., Кондакова И. В. и др. Связь экспрессии металлопротеиназы PAPP-A с экспрессией ростовых и транскрипционных факторов при раке эндометрия // Известия РАН. Сер. Биологическая. - 2013. - № 3. - С. 284-291.
Banejee P., Basu A., Datta D. et al. The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal // J Biol Chem. - 2011. -Vol. 286 (38). - P 33580-33590.
Darwish O.M., Kapur P., Youssef R.F. et al. Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma // Urology. - 2013. - Vol. 81 (3). - P 581-586.
Dodd K.M., Yang J., Shen M.H. et al. mTORC1 drives HIF-1 and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3 // Oncogene. - 2015. - Vol. 34 (17). - P. 2239-2250.
Fan L., Li P., Yin Z. et al. Ribosomal s6 protein kinase 4: a prognostic factor for renal cell carcinoma // Br. J. Cancer. - 2013. - Vol. 109 (5). - P. 1137-1146.
Figlin R. A., Kaufmann I., Brechbiel J. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for vercoming resistance to VEGFR and mTORC1 inhibitors // Int. J. Cancer. - 2013. - Vol. 133. - P 788-796.
Gao T., Furnari F., Newton A. C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth // Mol. Cell. - 2005. - Vol. 18. - P. 13-24.
Hager M., Haufe H., Alinger B., Kolbitsch C. pS6 Expression in normal renal parenchyma, primary renal cell carcinomas and their metastases // Pathol. Oncol. Res. - 2012. - Vol. 18 (2). - P. 277-283.
Mendoza M.C., Er E.E., Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation // Trends Biochem. Sci. - 2011. - Vol. 36. - P. 320-328.
Nishikawa M., Miyake H., Harada K., Fujisawa M. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy // Urol. Oncol. - 2014. - Vol. 32 (1). - P. 15-21.
Schultz L., Chaux A., Albadine R. et al. Immunoexpres-sion status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas // Am. J. Surg. Pathol. - 2011. - 35 (10). - P. 1549-1556.
Spirina L.V., Kondakova I.V., Choynzonov E.L. et al. Expression of vascular endothelial growth factor and transcription factors HIF-1 and NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpains activity // J. Cancer Res. Clin. Oncol. - 2013. - Vol. 139. - P. 625-633.
Thangavelu K., Pan C.Q., Karlberg T. et al. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism // Proc. Natl. Acad. Sci. USA. - 2012. - Vol. 109 (20). - P. 7705-7710.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...